[Skip to Content]
[Skip to Content Landing]
Comment & Response
June 2018

Adjunctive Intranasal Esketamine in Treatment-Resistant Depression—Reply

Author Affiliations
  • 1Department of Neuroscience, Janssen Research & Development, LLC, Titusville, New Jersey
  • 2Department of Neuroscience, Janssen Research & Development, LLC, San Diego, California
JAMA Psychiatry. 2018;75(6):654-655. doi:10.1001/jamapsychiatry.2018.0430

In Reply We thank Shouan and Grover for their interest in our recently published study.1 Regarding the question about the definition of treatment-resistant depression (TRD) used in the study, we would like to emphasize that this was a proof-of-concept study to evaluate the dose response with intranasal esketamine. Larger phase 3 studies are required before the patient population and the utility of esketamine can be fully evaluated in TRD.